Page 241 - Drug Class Review

Drug Effectiveness Review Project

Drugs Authors: Wilkinson et al. 54 Shire Phamaceuticals To investigate whether GAL significantly improves the core symptoms of AD Setting: Multi-center placebo galantamine N/A 18; 24; 36 mg/d 3 months 3 months 87 88; 56; 54 Male and female outpatients with mild to moderate AD as defined by NINCDS/ADRDA and MMSE (score 13-24) aged >45 years who were attending memory clinics; required to have appropriate caregiver Dementia secondary to causes other than AD or any condition considered likely to interfere with the trial in the opinion of the investigator Antidepress

Alzheimer Year: 2001 Country: UK Study design: RCT Sample size: 285

Final Report Update 1 Efficacy/Effectiveness STUDY: FUNDING: RESEARCH OBJECTIVE: DESIGN: INTERVENTION: Dose: Duration: Sample size: INCLUSION: EXCLUSION: OTHER MEDICATIONS/ INTERVENTIONS ALLOWED: Alzheimer's Drugs